1. Home
  2. STKE vs LUNG Comparison

STKE vs LUNG Comparison

Compare STKE & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

STKE

Sol Strategies Inc.

N/A

Current Price

$1.31

Market Cap

61.4M

Sector

N/A

ML Signal

N/A

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.50

Market Cap

72.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STKE
LUNG
Founded
2002
1995
Country
Canada
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.4M
72.2M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
STKE
LUNG
Price
$1.31
$1.50
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$6.81
AVG Volume (30 Days)
277.9K
339.5K
Earning Date
02-25-2026
02-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,456,249.00
$91,664,000.00
Revenue This Year
$45.67
$9.21
Revenue Next Year
N/A
$5.03
P/E Ratio
N/A
N/A
Revenue Growth
37.18
15.59
52 Week Low
$1.18
$1.31
52 Week High
$24.88
$9.37

Technical Indicators

Market Signals
Indicator
STKE
LUNG
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
STKE
LUNG

About STKE Sol Strategies Inc.

Sol Strategies Inc is engaged in investing in blockchain technologies and crypto currencies. Company executes its Investment Objective through three lines of effort: Treasury management: Maintaining a core portfolio of cryptocurrencies for long-term growth, enhanced with risk management strategies to minimize volatility, and generating yield through lending, staking, and liquidity provisioning; Private equity focused on early stage companies in the DeFi and blockchain sectors; and Active investments to generate yield through strategic activities, including Bitcoin mining and stalking and validating Solana.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: